The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The FDA approved the fourth natural food color additive this year, but how can you avoid the artificial dyes still out there?

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...

This approval marks a key milestone for Apotex, introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016, and reflecting the Company's commitment to expand its biologics ...

FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk Jul 2, 2025 Updated Jul 2, 2025 child scale weight ...